Skip to main content

Uecker Darrin's Form 4 filing

Pulse Biosciences, Inc. (PLSE) · filed Sep 15, 2025

Accession no.
0001437749-25-029104
Filed
Sep 15, 2025
Trade date
Sep 11-15, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.12M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Uecker DarrinCIK 0001276311Director, Officer (Chief Technology Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 11, 2025Common StockMOption exerciseAcquired+25,000$4.00+$100,000147,872Direct
Sep 11, 2025Common StockSSaleDisposed−25,000$14.78F2−$369,500122,872Direct
Sep 12, 2025Common StockMOption exerciseAcquired+25,000$4.00+$100,000147,872Direct
Sep 12, 2025Common StockSSaleDisposed−25,000$14.32F3−$358,000122,872Direct
Sep 15, 2025Common StockMOption exerciseAcquired+25,000$4.00+$100,000147,872Direct
Sep 15, 2025Common StockSSaleDisposed−25,000$15.77F4−$394,250122,872Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 11, 2025Common StockMOption exerciseDisposed−25,000$0.00$0156,534Direct
Sep 12, 2025Common StockMOption exerciseDisposed−25,000$0.00$0131,534Direct
Sep 15, 2025Common StockMOption exerciseDisposed−25,000$0.00$0106,534Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $14.41 to $15.14 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $13.80 to $14.76 per share.

Referenced by the price of 1 transaction in Table I.

F4

The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.18 to $17.20 per share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)